Marieke van Son

40 CHAPTER 2 34. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Pros- tate Cancer. Part 1: Screening, Diagno- sis, and Local Treatment with Curative Intent. Eur Urol. 2017;71(4):618-629. 35. Dasgupta P, Davis J, Hughes S. NICE guidelines on prostate cancer 2019. BJU international. 2019;124(1):1. 36. Komisarenko M, Martin LJ, Finelli A. Active surveillance review: contempo- rary selection criteria, follow-up, com- pliance and outcomes. Translational an- drology and urology. 2018;7(2):243-255. 37. Gill IS, Azzouzi AR, Emberton M, et al. Randomized Trial of Partial Gland Abla- tion with Vascular Targeted Photother- apy versus Active Surveillance for Low Risk Prostate Cancer: Extended Follow- up and Analyses of Effectiveness. The Journal of urology. 2018;200(4):786-793. 38. Tay KJ, Amin MB, Ghai S, et al. Surveil- lance after prostate focal therapy. World journal of urology. 2019;37(3):397-407. 39. Lennernas B, Majumder K, Damber JE, et al. Radical prostatectomy versus high-dose irradiation in localized/ locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes. Acta oncologica (Stockholm, Sweden). 2015;54(6):875-881.